Jonathan Wilde, PhD is the Chief Scientific Officer at Emugen Therapeutics, a private biotechnology company based in Woburn, MA that develops next-generation gene therapies for neurodevelopmental disorders. 

 

Dr. Wilde earned a Bachelor of Science in Biotechnology from The Pennsylvania State University and a PhD in Cell Biology, Stem Cells, and Development from the University of Colorado Anschutz Medical Campus, where he identified novel mechanisms regulating vitamin A’s function during early brain development. 

 

During his postdoctoral fellowship with Dr. Guoping Feng at The McGovern Institute for Brain Research at MIT, he developed cutting-edge genome editing approaches and engineered primate and mouse models of neurological disorders. 

 

Following his postdoc, Dr. Wilde was a group leader at the McGovern Institute where he continued to improve genome editing approaches and developed tools to assess their safety and efficacy in non-human primates. His multidisciplinary expertise spans molecular genetics, cellular and molecular neuroscience, developmental biology, genome editing, and genetic therapies.